Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis

Hacıhamdioğlu DÖ, Düzova A, Alehan D, Oğuz B, Beşbaş N. Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis. Turk J Pediatr 2015; 57: 9-16.Our purpose was to assess the relationship between serum fibroblast growth factor 23 (FGF23) and left ventricular function, carotid intima-media thickness (CIMT) and laboratory features in children on peritoneal dialysis (PD). The study population consisted of 17 patients (11 female; median age 7.83 years, range 0.66-17.75) undergoing PD for 22 months . Serum FGF23, serum phosphorus, calcium, intact parathyroid hormone (iPTH), 25(OH) vitamin D, 1,25(OH)2 vitamin D and Kt/V urea, left ventricular mass (LVM) and LVM index (LVMI) were assessed. Median FGF23 level was 29.92 pg/ml (22.7-74.76), phosphorus was 5.2 mg/dl (3.1-9.9), iPTH was 438 pg/ml , 25(OH) vitamin D was 11 ng/ml , 1,25(OH)2 vitamin D was 11 pg/ml , Kt/V urea was 2.33 (1.013.84). FGF23 level was independently associated with Kt/V urea (p

🔖

Bu Makaleye Atıf Yap

DÜZOVA, A., OĞUZ, B., HACIHAMDİOĞLU, D. Ö., BEŞBAŞ, N., ALEHAN, D. (2022). Circulating fibroblast growth factor 23 in children on peritoneal dialysis is associated with effective dialysis. Turkish Journal of Pediatrics, Cilt: 57 - Sayı: 1, 9–16. https://ajindex.com/articles/613223

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-513.
Meisinger C, Döring A, Löwel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006, 27: 1245-1250.
Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009; 45: 1161-1168.
Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561–568. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545- 2552. Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010; 14: 425-432.
Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43: 572-579.
Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol 2012; 27: 2129-2136.
Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011; 26: 945-951. CDC Growth Charts: Percentile Data Files with LMS Values. http://www.cdc.gov/growthcharts/percentile_ data_files.htm. [The last entry was made in March 2014.]
Nolph KD, Moore H